|
Name |
Arginyl-Asparagine
|
| Molecular Formula | C10H20N6O4 | |
| IUPAC Name* |
(2S)-4-amino-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoic acid
|
|
| SMILES |
C(C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)N)CN=C(N)N
|
|
| InChI |
InChI=1S/C10H20N6O4/c11-5(2-1-3-15-10(13)14)8(18)16-6(9(19)20)4-7(12)17/h5-6H,1-4,11H2,(H2,12,17)(H,16,18)(H,19,20)(H4,13,14,15)/t5-,6-/m0/s1
|
|
| InChIKey |
JSLGXODUIAFWCF-WDSKDSINSA-N
|
|
| Synonyms |
Arg-Asn; Arginyl-Asparagine; L-Arginyl-L-Asparagine; arginylasparagine; RN dipeptide; R-N Dipeptide; Arginine Asparagine dipeptide; Arginine-Asparagine dipeptide; CHEBI:157790; (2S)-4-amino-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoic acid
|
|
| CAS | 68040-95-9 | |
| PubChem CID | 53972225 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 288.3 | ALogp: | -6.0 |
| HBD: | 6 | HBA: | 6 |
| Rotatable Bonds: | 9 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 200.0 | Aromatic Rings: | 0 |
| Heavy Atoms: | 20 | QED Weighted: | 0.15 |
| Caco-2 Permeability: | -6.944 | MDCK Permeability: | 0.00124523 |
| Pgp-inhibitor: | 0 | Pgp-substrate: | 0.382 |
| Human Intestinal Absorption (HIA): | 0.038 | 20% Bioavailability (F20%): | 0.899 |
| 30% Bioavailability (F30%): | 0.988 |
| Blood-Brain-Barrier Penetration (BBB): | 0.347 | Plasma Protein Binding (PPB): | 7.80% |
| Volume Distribution (VD): | 0.475 | Fu: | 92.17% |
| CYP1A2-inhibitor: | 0.001 | CYP1A2-substrate: | 0.014 |
| CYP2C19-inhibitor: | 0.026 | CYP2C19-substrate: | 0.036 |
| CYP2C9-inhibitor: | 0.078 | CYP2C9-substrate: | 0.04 |
| CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.172 |
| CYP3A4-inhibitor: | 0.002 | CYP3A4-substrate: | 0.004 |
| Clearance (CL): | 2.058 | Half-life (T1/2): | 0.619 |
| hERG Blockers: | 0.047 | Human Hepatotoxicity (H-HT): | 0.033 |
| Drug-inuced Liver Injury (DILI): | 0.012 | AMES Toxicity: | 0.037 |
| Rat Oral Acute Toxicity: | 0.028 | Maximum Recommended Daily Dose: | 0.01 |
| Skin Sensitization: | 0.163 | Carcinogencity: | 0.038 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.018 |
| Respiratory Toxicity: | 0.059 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC001514 | ![]() |
0.578 | D0F5DO | ![]() |
0.537 | ||
| ENC000142 | ![]() |
0.537 | D07WXE | ![]() |
0.452 | ||
| ENC000937 | ![]() |
0.360 | D09PPG | ![]() |
0.425 | ||
| ENC000795 | ![]() |
0.311 | D0TP2W | ![]() |
0.351 | ||
| ENC000123 | ![]() |
0.300 | D02HFD | ![]() |
0.351 | ||
| ENC002451 | ![]() |
0.299 | D0Z0MG | ![]() |
0.349 | ||
| ENC000137 | ![]() |
0.293 | D01JIA | ![]() |
0.328 | ||
| ENC001902 | ![]() |
0.288 | D07JVS | ![]() |
0.287 | ||
| ENC001760 | ![]() |
0.276 | D0UP9M | ![]() |
0.287 | ||
| ENC002115 | ![]() |
0.275 | D0O5WD | ![]() |
0.268 | ||